Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) EBIT (2019 - 2023)

Historic EBIT for ADC Therapeutics (ADCT) over the last 5 years, with Q3 2023 value amounting to -$36.1 million.

  • ADC Therapeutics' EBIT fell 106085.42% to -$36.1 million in Q3 2023 from the same period last year, while for Sep 2023 it was -$7.8 billion, marking a year-over-year increase of 8759.07%. This contributed to the annual value of $4950.0 for FY2022, which is 10000.24% up from last year.
  • As of Q3 2023, ADC Therapeutics' EBIT stood at -$36.1 million, which was down 106085.42% from $3.0 billion recorded in Q2 2023.
  • ADC Therapeutics' 5-year EBIT high stood at $3.0 billion for Q2 2023, and its period low was -$62.8 billion during Q4 2021.
  • Over the past 5 years, ADC Therapeutics' median EBIT value was -$36.1 million (recorded in 2023), while the average stood at -$4.2 billion.
  • As far as peak fluctuations go, ADC Therapeutics' EBIT plummeted by 16102302863.17% in 2021, and later skyrocketed by 445233.61% in 2023.
  • Over the past 5 years, ADC Therapeutics' EBIT (Quarter) stood at -$35732.0 in 2019, then soared by 99.85% to -$52.43 in 2020, then plummeted by 119747081612.06% to -$62.8 billion in 2021, then skyrocketed by 82.9% to -$10.7 billion in 2022, then skyrocketed by 99.66% to -$36.1 million in 2023.
  • Its EBIT was -$36.1 million in Q3 2023, compared to $3.0 billion in Q2 2023 and -$51.6 million in Q1 2023.